Skip Navigation

Cardiovascular Research 2000 47(3):602-608; doi:10.1016/S0008-6363(00)00019-5
© 2000 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schrammel, A.
Right arrow Articles by Mayer, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schrammel, A.
Right arrow Articles by Mayer, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Inhibition of purified soluble guanylyl cyclase by L-ascorbic acid

Astrid Schrammela,*, Doris Koesling1,b, Kurt Schmidta and Bernd Mayera

aInstitut für Pharmakologie und Toxikologie, Karl-Franzens-Universität Graz, Universitätsplatz 2, 8010 Graz, Austria
bInstitut für Pharmakologie, Freie Universität Berlin, Thielallee 69-73, D-14195 Berlin, Germany

* Corresponding author astrid.schrammel{at}kfunigraz.ac.at

Objective: L-Ascorbic acid has been described to exert multiple beneficial effects in cardiovascular disorders associated with impaired nitric oxide (NO)/cGMP signalling. The aim of the present study was to investigate the effect of vitamin C on the most prominent physiological target of endogenous and exogenous NO, i.e. soluble guanylyl cyclase (sGC). Methods: To address this issue we used a highly purified enzyme preparation from bovine lung (from the slaughterhouse). Enzymic activity was measured by a standard assay based on the conversion of [{alpha}-32P]GTP to [32P]cGMP and the subsequent quantification of the radiolabelled product. NO was quantified using a commercially available Clark-type electrode. Results: Stimulation of sGC by the NO donor 2,2-diethyl-1-nitroso-oxyhydrazine was inhibited by ascorbate with an IC50 of ~2 µM. Maximal enzyme inhibition (~70%) was observed at 0.1–1 mM vitamin C. Stimulation of sGC by the NO-independent activator protoporphyrin-IX was also inhibited with similar potency. The effect of ascorbate on sGC was largely antagonised by reduced glutathione (1 mM) and the specific iron chelator diethylenetriaminepentaacetic acid (0.1 mM). Electrochemical experiments revealed that NO is potently scavenged by vitamin C. Consumption of NO by ascorbate was prevented by reduced glutathione (1 mM), diethylenetriaminepentaacetic acid (0.1 mM) and superoxide dismutase (500 units/ml) whereas up to 5000 units/ml superoxide dismutase failed to restore sGC activity. Conclusions: Our results suggest that physiological concentrations of L-ascorbic acid diminish cGMP accumulation via both scavenging of NO and direct inhibition of sGC.

KEYWORDS Nitric oxide; Oxygen consumption; Second messengers; Smooth muscle; Vasoconstriction/dilatation

1 Present address: Institut für Pharmakologie, Ruhr Universität Bochum, MA N1/39, D-44780 Bochum, Germany.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
A. Kollau, M. Beretta, A. C. F. Gorren, M. Russwurm, D. Koesling, K. Schmidt, and B. Mayer
Bioactivation of Nitroglycerin by Ascorbate
Mol. Pharmacol., July 1, 2007; 72(1): 191 - 196.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
J. M. Williams, C. R. White, M. M. Chang, E. R. Injeti, L. Zhang, and W. J. Pearce
Chronic hypoxic decreases in soluble guanylate cyclase protein and enzyme activity are age dependent in fetal and adult ovine carotid arteries
J Appl Physiol, June 1, 2006; 100(6): 1857 - 1866.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. M. Carcamo, A. Pedraza, O. Borquez-Ojeda, B. Zhang, R. Sanchez, and D. W. Golde
Vitamin C Is a Kinase Inhibitor: Dehydroascorbic Acid Inhibits I{kappa}B{alpha} Kinase {beta}
Mol. Cell. Biol., August 1, 2004; 24(15): 6645 - 6652.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
S. Karanth, W. H. Yu, C. A Mastronardi, and S. M. McCann
Inhibition of Stimulated Ascorbic Acid and Luteinizing Hormone-Releasing Hormone Release by Nitric Oxide Synthase or Guanyl Cyclase Inhibitors
Experimental Biology and Medicine, January 1, 2004; 229(1): 72 - 79.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Matsumoto, L. V. d'uscio, D. Eguchi, M. Akiyama, L. A. Smith, and Z. S. Katusic
Protective Effect of Chronic Vitamin C Treatment on Endothelial Function of Apolipoprotein E-Deficient Mouse Carotid Artery
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 103 - 108.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. Perez-Cruz, J. M. Carcamo, and D. W. Golde
Vitamin C inhibits FAS-induced apoptosis in monocytes and U937 cells
Blood, July 1, 2003; 102(1): 336 - 343.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. A. Kowluru, J. Tang, and T. S. Kern
Abnormalities of Retinal Metabolism in Diabetes and Experimental Galactosemia: VII. Effect of Long-Term Administration of Antioxidants on the Development of Retinopathy
Diabetes, August 1, 2001; 50(8): 1938 - 1942.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.